# Transcode Therapeutics

Transcode Therapeutics is an other.

## Overview

- **Organization type:** other
- **Assets under management:** Undisclosed
- **Website:** https://transcodetherapeutics.com
- **LinkedIn:** https://www.linkedin.com/company/transcodetherapeutics

## Regulatory record

- **Reports private funds:** No

## About

TransCode Therapeutics is a clinical-stage company in the healthcare sector, focused on immuno-oncology and RNA therapeutics. The company develops targeted therapies, such as TTX-MC138, which targets microRNA-10b in metastatic cancer treatment. Founded in 2016, TransCode Therapeutics is based in Boston, Massachusetts, and utilizes its TTX iron oxide nanoparticle delivery platform.

## Questions

### Who runs investment decisions at Transcode Therapeutics?

Transcode Therapeutics is a publicly traded biotechnology company, not a family office or investment firm. Investment decisions are made by its board of directors and management team, whose names are disclosed in SEC filings.

### How does Transcode source proprietary deal flow?

Transcode develops its own pipeline of siRNA therapeutics internally. The company has not disclosed any in-licensing or partnering activity for its core platform.

### What investment stages does Transcode typically target?

Transcode does not make investments. It is a therapeutic developer targeting preclinical and clinical-stage development of its own drug candidates.

### Which sectors does Transcode explicitly avoid?

Transcode focuses exclusively on RNA therapeutics for oncology and fibrosis. It does not operate in other therapeutic areas or asset classes.

## Related profiles

- [CV Sciences](https://altss.com/profile/cv-sciences-inc)
- [Trinseo PLC](https://altss.com/profile/trinseo-plc)

---

Last updated: 2026-05-30T22:59:29.032Z

Canonical page: https://altss.com/profile/transcode-therapeutics-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology